Standard myeloablative allogeneic stem cell transplantation (allo-SCT) is a well-established therapy for patients with acute myeloid leukemia (AML). However, because of the high incidence of transplant-related mortality (TRM), this procedure is limited to younger patients in good medical condition. 1 Reduced-intensity conditioning (RIC) regimens have emerged as an attractive modality to decrease TRM. 2, 3 However, the issue of possible higher relapse rate after RIC-allo-SCT is still under /day as continuous infusion for 7 days). Patients who failed to enter complete remission after this first induction regimen, received a second course of salvage induction with idarubicin (8 mg/m 2 /day for 5 days) instead of daunorubicin and cytarabine (100 mg/m 2 /day as continuous infusion for 7 days). G-CSF was not routinely given after the initial or the salvage induction chemotherapy. Once complete remission was achieved, and after neutrophils and platelets had recovered to 1.0 Â 10 9 /l and 100 Â 10 9 /l, respectively, patients usually received a first consolidation chemotherapy course consisting of cytarabine (100 mg/m 2 /day subcutaneously for 7 days) and daunorubicin (60 mg/m 2 /day for 2 days). c Two patients from the 'donor' group were not transplanted in first complete remission. They relapsed just before entry to allo-SCT, subsequently received a new induction chemotherapy course, and then proceeded to RIC-allo-SCT in second complete remission and refractory disease respectively. Letters to the Editor debate, [4] [5] [6] and no randomized studies between RIC-allo-SCT for AML and chemotherapy alone are yet available. 7 This updated analysis describes the long-term results of 95 previously reported 8 consecutive AML patients, diagnosed between 1999 and 2003 in a single institution, and who were considered as potential candidates for RIC-allo-SCT. Detailed methods were previously published. 8 Using a genetic randomization through a 'donor' versus 'no donor' comparison, the aim of this updated analysis was to assess the benefit of RIC-allo-SCT for adult AML and its impact on clinical outcome. In this series, 35 patients (37%; 'donor' group) had an 'identified' HLAidentical sibling donor, while the remaining 60 patients had no HLA-matched related donor ('no donor' group). As per institutional policy, HLA-matched unrelated donors were not considered during the study period. 8 No significant differences in patients or AML features were found between the two groups ( Table 1 ). In the 'donor' group, 25 patients (71%; median age, 51 (range, 26-60)) could actually proceed to the RIC-allo-SCT. The 10 remaining patients with an identified donor did not receive allo-SCT because of early relapse after complete remission (n ¼ 2), patient or donor refusal (n ¼ 6) and psychiatric disorders appearing before allo-SCT (n ¼ 2). The latest median follow-up is 4.8 (range, 3.5-7.2) years. In an 'intention-to-treat' analysis, leukemia-free survival (LFS) was significantly higher in the 'donor' group as compared with the 'no donor' group (P ¼ 0.003; 60 versus 23% at 7 years). When restricting the analysis to patients who could actually receive the RIC-allo-SCT, the difference in LFS was also significant between this group of 25 patients ('transplant' group) and the remaining 70 patients ('no transplant' group) who did not receive allo-SCT (P ¼ 0.0002; 72 versus 24% at 7 years). In the 'transplant' group, RIC-allo-SCT was performed at a median of 209 (range, 119-413) days after diagnosis. No major toxicities were encountered during RIC administration, and only three patients died from TRM, for a cumulative incidence of TRM of 12% (95% CI, 3-32%). This relatively low TRM translated towards a significantly higher overall survival (OS) in the 'transplant' group as compared with the 'no transplant' group (P ¼ 0.0003). In the 'intention-to-treat' analysis, OS was still significantly higher in the 'donor' group as compared with the 'no donor' group (P ¼ 0.003; Figure 1) . After controlling for all relevant factors, in the multivariate analysis, only actual performance of RIC-allo-SCT (P ¼ 0.0005; RR ¼ 4.1; 95% CI, 1.8-9.1), was significantly predictive of an improved LFS.
On the basis of these long-term results, and other studies with comparable long follow-up, 9, 10 we conclude that if a matchedrelated donor is identified, RIC-allo-SCT should be proposed because it represents a valid and potentially curative option for AML patients not eligible for standard myeloablative allo-SCT.
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We thank the nursing staff for providing excellent care for our patients and the physicians of the Hematology Department at the Institut Paoli-Calmettes for their important study contributions and dedicated patient care. We also thank the 'Association pour la The detection of the Janus kinase 2 (JAK2) mutation V617F (JAK2 mutV617F ) has become fundamental in the differential diagnosis of myeloproliferative neoplasms (MPNs), particularly polycythemia vera (X90% of cases), essential thrombocythemia and chronic idiopathic myelofibrosis (50-70% cases of each). 1 Although several studies addressing the JAK2 genotype in MPN as well as the hematopoietic progenitors targeted by JAK2 mutation and the frequency of this event based on molecular analyses of purified bone marrow cell populations (both myeloid and lymphoid) have already been published, [2] [3] [4] there is to date no published technique for the morphological identification of JAK2 mutV617F positive cells in MPN. Therefore, in this study, we describe a novel JAK2 mutV617F -specific in situ PCR (JAK2 mutV617F isPCR) using an optimized isPCR technique 5 on formalin-fixed and decalcified bone marrow samples (fixation 24-48 h in 4% buffered formalin solution, decalcification 24 h in 0.5 M EDTA disodium salt/ 0.5 M NaOH solution, pH 7.2). Allele-specific (AS) PCR amplification was carried out as conventional solution-based as well as in situ as described, 5-7 using a JAK2 mutV617F forward oligonucleotide primer (JAK2 mutV617F forward 5 0 -TTT TAA ATT ATG GAG TAT GTT-3 0 (the underlined final base anneals at the site of the GXT mutation) and an unmutated forward JAK2 primer as wild-type control (JAK2 unmutated forward 5 0 -TTT TAA ATT ATG GAG TAT GTG-3 0 ) in combination with a reverse primer annealing downstream of the JAK2 mutV617F mutation (JAK2 reverse 5 0 -GTT TAC ACT GAC ACC TAG CTG-3 0 ). Initially, the specificity of the conventional JAK2 mutV617F AS-PCR was analyzed using sample material from JAK2 mutV617F -positive (n ¼ 68) and -negative (n ¼ 62) cases of MPN that had previously been identified using direct sequencing 8 as well as in DNA from normal tissue samples (n ¼ 21). All JAK2 mutV617F -positive MPN showed specific PCR products in conventional JAK2 mutV617F AS-PCR experiments, whereas no amplificates were detectable in unmutated DNA samples from JAK2 mutV617F -negative MPN or in DNA from normal tissue samples (Figure 1 ). However, in one tissue sample that had previously been diagnosed as JAK2 mutV617F -negative ET (Figure 2a) , a weak specific PCR product was detected using solution based JAK2 mutV617F AS-PCR (Figure 1 ), lane 3. Reanalysis of this sample using direct sequencing with a reduced background reaction identified a JAK2 mutV617F mutation of B5% (calculated as the percentage of mutant allele compared to total peak height 9 ; Figure 2b ). Owing to the fact that direct sequencing has a lower sensitivity for the detection of the JAK2 mutV617F mutation than other, more sensitive methods such as AS-PCR, restriction fragment length polymorphism (RFLP) or semiquantitative real-time PCR, 10,11 the afore described identification of a JAK2 mutV617F -positive case of MPN previously diagnosed as JAK2 mutV617F -negative MPN using JAK2 mutV617F AS-PCR is in
